Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00428948
Other study ID # 156-04-251
Secondary ID 2006-002768-24
Status Completed
Phase Phase 3
First received January 26, 2007
Last updated February 1, 2013
Start date January 2007
Est. completion date January 2012

Study information

Verified date February 2013
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationCanada: Health CanadaArgentina: Ministry of HealthAustralia: Human Research Ethics CommitteeUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyFrance: National Consultative Ethics Committee for Health and Life SciencesGermany: Federal Institute for Drugs and Medical DevicesItaly: Ethics CommitteeBelgium: Ethics CommitteeNetherlands: Independent Ethics CommitteePoland: Ethics CommitteeRomania: Ethics CommitteeRussia: Ethics CommitteeJapan: Ministry of Health, Labor and WelfareDenmark: National Board of Health
Study type Interventional

Clinical Trial Summary

This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.


Description:

The current study will evaluate whether tolvaptan will be potentially beneficial, while maintaining an adequate safety profile, by reducing the rate of total renal volume increase, while impacting the onset, severity and progression of other important consequences of ADPKD.


Recruitment information / eligibility

Status Completed
Enrollment 1445
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- GFR estimated at =60 mL/ min

- Diagnosis of ADPKD and rapidly progressive kidney growth (total volume =750 cc) by Magnetic Resonance Imaging (MRI) at randomization

- Legal adult age and able to give Informed Consent

- Willingness to comply with reproductive precautions if female

Exclusion Criteria:

- Prior exposure to tolvaptan or other experimental PKD therapies

- Currently taking medication for purpose of affecting PKD cysts

- Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods

- In the opinion of the study investigator or sponsor may present a safety risk or confound study objectives

- Patients who are unlikely to adequately comply with study procedures

- Patients having contraindications to MRI

- Patients taking medications or having any illnesses likely to affect ADPKD outcomes.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
tolvaptan
oral tablet split-dose regimens (45/15mg, 60/30 mg or 90/30 mg) by mouth twice a day on awakening and approximately 9 hours later for 36 months. Daily dose regimen based on maximally tolerated dose.
Placebo
oral tablet split-dose regimens (45/15mg Placebo, 60/30 mg Placebo or 90/30 mg Placebo) by mouth twice a day on awakening and approximately 9 hours later for 36 months. Daily dose regimen based on maximally tolerated dose.

Locations

Country Name City State
Argentina Hospital Municipal de Vicente Lopez, Dr Bernardo Houssay Buenos Aires
Argentina Hosptial Universitario Austral Buenos Aires
Argentina Instituto de Nefrología, Nefrology SA Buenos Aires
Argentina Hospital Privado-Centro Medico de Cordoba Cordoba
Argentina Sanatorio Allende Cordoba
Australia Queen Elizebeth Hospital Adelaide
Australia Royal Adelaide Hospital Adelaide
Australia Princess Alexandra Hospital Brisbane
Australia Melbourne Renal Research Group Melbourne
Australia Royal Melbourne Hospital Melbourne
Australia Royal Perth Hospital Perth
Australia Royal North Shore Hospital Sydney
Australia Westmead Hospital Sydney
Belgium UZ Brussel Brussel
Belgium Ucl-St Luc Brussels
Belgium UZ Gent Gent
Canada Queen Elizabeth II Health Science Center, Division of Nephrology Halifax Nova Scotia
Canada Hospital du Sacre- Coeur de Montreal Montreal Quebec
Canada Royal Victoria Hospital Montreal Quebec
Denmark Herlev Amtssygehus Herlev
Denmark Odense Universitetshospital Odense
France CHU-Hopital Pellegrin Bordeaux
France CHU - Hôpital Clémenceau Caen Cedex
France Hôpital Edouard Herriot Lyon Cedex 3
France Hôpital de la Conception Marseille
France CHU - Hôpital Lapeyronie Montpellier
France Hopital Bichat-Claude Bernard Paris
France Centre Hospitalier Universitaire Reims cedex
France CHU - Hôpital Nord Saint-Etienne Cedex 2
France Hopital Rangueil Toulouse Cedex 09
Germany Universitätsklinikum Carl Gustav Carus Dresden
Germany Nephrologische Gemeinschaftspraxis/Dialysezentrum Düsseldorf
Germany Klinik für Nieren- und Hochdruckkrankheiten Essen
Germany Universitätsklinikum Freiburg Freiburg
Germany Universitätskliniken Heidelberg Heidelberg
Germany UH Erlangen/Nürnberg Nuernberg
Italy Ospedali Riuniti di Bergamo Bergamo
Italy Università Vita e Salute, Ospedale San Raffaele Milano
Italy Policlinico di Modena Modena
Italy Policlinico Napoli
Italy IRCCS Fondazione Salvatore Maugeri Pavia
Japan Nippon Medical School Hospital Bunkyo-ku Tokyo
Japan Tokyo Medical & Dental University Hospital, Faculty of Medicine Bunkyo-ku Tokyo
Japan Chiba University Hospital Chiba
Japan National Hospital Organization Chiba-East Hospital Chiba
Japan Kyusyu University Hospital Fukuoka
Japan Fukushima Medical University Hospital Fukushima
Japan Hamamatsu University School of Medicine, University Hospital Hamamatsu Shizuoka
Japan Hiroshima University Hospital Hiroshima
Japan Tokai University Hospital Isehara Kanagawa
Japan Teikyo University Hospital Itabashi-ku Tokyo
Japan Shuwa General Hospital Kasukabe Saitama
Japan Saitama Medical Center Kawagoe Saitama
Japan Toranomon Hospital Kajigaya Kawasaki Kanagawa
Japan Kumamoto Univeristy Hospital Kumamoto
Japan Kyoto University Hospital Kyoto
Japan National Hospital Organization Kyoto Medical Center Kyoto
Japan The Jikei University Hospital Minato-Ku Tokyo
Japan Toranomon Hospital Minato-ku Tokyo
Japan Kyorin University Hospital Mitaka Tokyo
Japan Niigata University Medical & Dental Hospital Niigata
Japan Ohno Memorial Hospital Osaka
Japan Osaka City University Hospital Osaka-City Osaka
Japan Kitasato University Hospital Sagamihara Kanagawa
Japan Saitama Medical Center Jichi Medical University Saitama
Japan Hokkaido University Hospital Sapporo Hokkaido
Japan Tohoku University Hospital Sendai Miyagi
Japan Jichi Medical School Hospital Shimotsuke Tochigi
Japan Tokyo Women's Medical University Hospital Shinjuku-ku Tokyo
Japan Osaka University Hospital Suita Osaka
Japan Fujita Health University Hospital Toyoake Aichi
Netherlands VU Medisch Centrum Amsterdam
Netherlands UMCG Groningen Groningen
Poland Oddzial Nefrologiczny Stacja Dializ Ciechanow
Poland Akademickie Centrum Kliniczne AMG Gdansk
Poland Samodzielny Publiczny Szpital Kliniczny nr 1, Akademickie Centrum Kliniczne AMG Gdansk
Poland Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Szpital Uniwersytecki w Krakowie Krakow
Poland SOP ZOZ Uniwersytecki Szpital Kliniczny Lodz
Poland Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie Lublin
Poland Klinika Chorób Wewnetrznych i Nefrologii Warsaw
Poland Miedzyleski Szpital Specjalistyczny w Warszawie Warsaw
Poland Szpital Praski p.w. Przemienienia Panskiego, Samodzielny Publiczny Zaklad Opieki Zdrowotnej Warszawa
Poland Szpital Praski, Samodzielny Publiczny ZOZ Warszawa
Poland Akademicki Szpital Kliniczny im J Mikulicza Radeckiego Wroclaw
Romania Institutul Clinic Fundeni Bucharest
Romania Spitalul Clinic de Nefrologie Dr. Carol Davila Bucharest
Romania Spitalul Clinic "C.I.Parhon" Iasi
Russian Federation Kemerovo Medical Academy, Regional Clinical Hospital Kemerovo
Russian Federation City Clinical Hospital #52 Moscow
Russian Federation City Mariinskiy Hospital St. Petersburg
Russian Federation Leningrad Regional Clinical Hospital St.-Petersburg
Russian Federation Tomsk Regional Clinical Hospital Tomsk
United Kingdom Belfast City Hospital Belfast
United Kingdom Oueen Elizabeth Hospital Birmingham
United Kingdom Sussex Renal Unit Royal Sussex County Hospital Brighton
United Kingdom Uhcw Mhs Trust Coventry
United Kingdom Royal Infirmary Edinburgh
United Kingdom Raigmore Hospital Inverness
United Kingdom King's College Hospital London
United Kingdom Royal Free and University College Medical School London
United Kingdom St. George's Hospital London
United Kingdom Royal Hallamshire Hospital Sheffield
United Kingdom Morriston Hospital Swansea
United States Emory University School of Medicine Atlanta Georgia
United States John Hopkins School of Medicine Baltimore Maryland
United States Renal Associates of Baton Rough, L.L.C. Baton Rouge Louisiana
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Tufts- New England Medical Center Boston Massachusetts
United States Erie County Medical Center Buffalo New York
United States University of North Carolina, UNC, Kidney Center Chapel Hill North Carolina
United States Charleston Nephrology Associates Charleston South Carolina
United States University of Virginia, Nephrology Clinical Research Center Charlottesville Virginia
United States Northwestern University Chicago Illinois
United States Kidney and Hypertension Center Cincinnati Ohio
United States University Hospitals of Cleveland/Case Cleveland Ohio
United States University of Colorado Health Sciences Center Denver Colorado
United States East Carolina University Greenville North Carolina
United States Nephrology Associates of Westchester Hawthorne New York
United States Jacksonville Center for Clinical Research Jacksonville Florida
United States University of Kansas Medical Center Kansas City Kansas
United States Coastal Clinical Research Mobile Alabama
United States University of South Alabama Mobile Alabama
United States Nephrology Associates, P.C. Nashville Tennessee
United States Vanderbilt University Medical Center Nashville Tennessee
United States Yale University School of Medicine New Haven Connecticut
United States Columbia University Medical Center New York New York
United States The Rogosin Institute New York New York
United States University of Pennsylvania Medical Center Philadelphia Pennsylvania
United States Coastal Nephrology Associates Research Center, LLC Port Charlotte Florida
United States Northwest Renal Clinic, Inc. Portland Oregon
United States Apex Research of Riverside Riverside California
United States Mayo Medical Center Rochester Minnesota
United States Stanford University Medical Center Stanford California

Sponsors (2)

Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Pharmaceutical Co., Ltd.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Belgium,  Canada,  Denmark,  France,  Germany,  Italy,  Japan,  Netherlands,  Poland,  Romania,  Russian Federation,  United Kingdom, 

References & Publications (2)

Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003 Oct;9(10):1323-6. Epub 2003 Sep 21. — View Citation

Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004 Apr;10(4):363-4. Epub 2004 Feb 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of total kidney volume change(%) 36 months No
Secondary Time to onset of multiple ADPKD outcomes ADPKD outcomes include new onset hypertension, worsening hypertension, renal pain, worsening albuminuria and worsening renal function 36 months No
Secondary Evaluate long-term efficacy of tolvaptan in ADPKD using single clinical 4-markers of ADPKD progression 36 months No
Secondary Evaluate long-term safety of tolvaptan through standard clinical measures. 36 months Yes
Secondary Evaluate pharmacokinetic (PK), pharmacodynamic (PD) and exploratory parameters for tolvaptan in ADPKD. 36 months No
See also
  Status Clinical Trial Phase
Completed NCT04536688 - A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1